MDI-1228 is under clinical development by Henan Maiyingnuo Pharmaceutical Technology and currently in Phase I for Allergic Conjunctivitis. According to GlobalData, Phase I drugs for Allergic Conjunctivitis have a 92% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MDI-1228’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
MDI-1228 is under development for the treatment of atopic dermatitis and allergic conjunctivitis. The drug candidate is administered by topical and ophthalmic route in the form of gel.
Henan Maiyingnuo Pharmaceutical Technology overview
Henan Maiyingnuo Pharmaceutical Technology (Maiyingnuo Pharmaceutical) operate in healthcare sector. Maiyingnuo Pharmaceutical is headquartered in Zhengzhou, Henan, China.
For a complete picture of MDI-1228’s drug-specific PTSR and LoA scores, buy the report here.